Bringing the fundamentals into focus…
Back to Ligand Pharmaceuticals Incorporated
How Ligand Pharmaceuticals Incorporated stacks up
LGND · against 217 other Healthcare companies of similar size
Valuation
50/ 100
Below the middle of the pack.
Ranked #124 of 218 · scores higher than 42% of peers
Bars: peers in each 10-point band of the valuation score29 peers with a valuation score of 50–59, including LGND · Click a bar to see the companies
Why valuation scores 50?
Weighted metrics compared with all Healthcare companies.A mix: stronger earnings yield and free cash flow yield, but weaker EBITDA yield than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 61% of peers. EBITDA yield: 2.1% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 61% of peers. Free cash flow yield: 2.1% vs peer median 0.0%
- higher earnings for the price paid: stronger than 62% of peers. Earnings yield: 3.2% vs peer median 1.5%
Metric by metric
Position: dot = LGND, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LGND | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 215 reported | 3.0% | 2.6% | 57% | 30% | |
| EBITDA yieldHigher is better · 216 reported | 2.2% | 4.8% | 29% | 50% | |
| Free cash flow yieldHigher is better · 123 reported | 1.9% | 1.2% | 56% | 20% | |
| Book yieldHigher is better · 216 reported | 15.5% | 26.2% | 33% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around LGND| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 3 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 4 | 10.4B USD | 96 | 64 | |
| 5 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 119 | 4.0B USD | 51 | 72 | |
| 124 | 558.5B INR (≈$6.7B) | 50 | 47 | |
| 124 | 521.3B INR (≈$6.3B) | 50 | 69 | |
| 124 | 9.0B USD | 50 | 78 | |
| 124 | 6.3B USD | 50 | 78 | |
| 128 | 4.0B USD | 49 | 46 | |
| 128 | 10.8B USD | 49 | 35 | |
| 130 | 34.2B CNY (≈$4.8B) | 48 | 59 | |
| 130 | 7.2B USD | 48 | 43 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score